Wnt/β-catenin pathway is a key signaling pathway to trastuzumab resistance in gastric cancer cells

BACKGROUND: Trastuzumab is the only approved target agent for the first-line treatment of human epidermal growth factor receptor-2 (HER-2) positive gastric cancer; however, trastuzumab resistance is a major problem in clinical practice. To comprehend the mechanism of trastuzumab resistance, we focus...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Yuna, Bae, Yoo Jin, Kim, Jie-Hyun, Kim, Hyunki, Shin, Su-Jin, Jung, Da Hyun, Park, Hyojin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10542239/
https://www.ncbi.nlm.nih.gov/pubmed/37773114
http://dx.doi.org/10.1186/s12885-023-11447-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10542239/
https://www.ncbi.nlm.nih.gov/pubmed/37773114
http://dx.doi.org/10.1186/s12885-023-11447-4

Ejemplares similares